FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232912661> ?p ?o ?g. }

• W4232912661 endingPage "545" @default.
• W4232912661 startingPage "545" @default.
• W4232912661 abstract "545 Background: Bevacizumab is associated with both arterial (ATE) and venous thromboembolic (VTE) events, estimated to be </=15% from clinical trials. Our objectives were to 1) characterize the incidence of ATE or VTE among mCRC patients receiving bevacizumab in a non-clinical trial setting; 2) determine patient and treatment-related factors that predispose to an increased risk of ATE or VTE; and 3) explore how thromboembolism is managed and whether bevacizumab is discontinued and/or resumed after an event. Methods: A random sample of mCRC patients diagnosed between 2008 and 2009, referred to 1 of 5 regional cancer centers in British Columbia, and who were offered bevacizumab was reviewed. Summary statistics were used to describe and compare clinical factors between those who experienced an ATE or VTE and those who did not. Results: Of the 200 mCRC patients offered bevacizumab, 10 never received the drug and 12 were lost to follow up. Among the 178 remaining patients, median age was 61 years, 103 (58%) were male, and 121 (85%) had ECOG 0 to 1. A total of 39 patients (28%) experienced at least 1 documented thromboembolic event. Compared to patients who developed a clot, those who did not had similar median age (62 vs 61), gender distribution (23% men and 20% women), ECOG 0 to 1 (84% vs 85%) and body mass index (26.4 vs 25.3). However, the mean number of bevacizumab doses was higher in the group with thromboembolism (12.6 vs 9.0), suggesting a potential dose-related effect. There were a total of 43 VTE and 5 ATE events documented, with 7 of the 39 patients (18%) experiencing more than 1 event. Bevacizumab was held or discontinued in 60% of cases, but it was continued in 25% of the cases; 4% of the events were fatal, and 10% of the VTE/ATE occurred after bevacizumab was stopped. Conclusions: The incidence of ATE and VTE in a non-study setting appears to be higher than that reported in clinical trials. There may be a dose-related effect. Bevacizumab was not consistently held or discontinued in the setting of a VTE or ATE. Development of guidelines for the management of thromboembolism with bevacizumab may be warranted." @default.
• W4232912661 created "2022-05-12" @default.
• W4232912661 creator A5039850848 @default.
• W4232912661 creator A5087002295 @default.
• W4232912661 date "2013-02-01" @default.
• W4232912661 modified "2023-10-18" @default.
• W4232912661 title "Risk of arterial (ATE) and venous thromboembolism (VTE) in a population-based cohort of bevacizumab-treated metastatic colorectal cancer (mCRC) patients." @default.
• W4232912661 doi "https://doi.org/10.1200/jco.2013.31.4_suppl.545" @default.
• W4232912661 hasPublicationYear "2013" @default.
• W4232912661 type Work @default.
• W4232912661 citedByCount "1" @default.
• W4232912661 countsByYear W42329126612017 @default.
• W4232912661 crossrefType "journal-article" @default.
• W4232912661 hasAuthorship W4232912661A5039850848 @default.
• W4232912661 hasAuthorship W4232912661A5087002295 @default.
• W4232912661 hasConcept C120665830 @default.
• W4232912661 hasConcept C121332964 @default.
• W4232912661 hasConcept C121608353 @default.
• W4232912661 hasConcept C126322002 @default.
• W4232912661 hasConcept C141071460 @default.
• W4232912661 hasConcept C143998085 @default.
• W4232912661 hasConcept C2776694085 @default.
• W4232912661 hasConcept C2777802072 @default.
• W4232912661 hasConcept C2780868729 @default.
• W4232912661 hasConcept C2908647359 @default.
• W4232912661 hasConcept C2991741193 @default.
• W4232912661 hasConcept C526805850 @default.
• W4232912661 hasConcept C61511704 @default.
• W4232912661 hasConcept C71924100 @default.
• W4232912661 hasConcept C72563966 @default.
• W4232912661 hasConcept C99454951 @default.
• W4232912661 hasConceptScore W4232912661C120665830 @default.
• W4232912661 hasConceptScore W4232912661C121332964 @default.
• W4232912661 hasConceptScore W4232912661C121608353 @default.
• W4232912661 hasConceptScore W4232912661C126322002 @default.
• W4232912661 hasConceptScore W4232912661C141071460 @default.
• W4232912661 hasConceptScore W4232912661C143998085 @default.
• W4232912661 hasConceptScore W4232912661C2776694085 @default.
• W4232912661 hasConceptScore W4232912661C2777802072 @default.
• W4232912661 hasConceptScore W4232912661C2780868729 @default.
• W4232912661 hasConceptScore W4232912661C2908647359 @default.
• W4232912661 hasConceptScore W4232912661C2991741193 @default.
• W4232912661 hasConceptScore W4232912661C526805850 @default.
• W4232912661 hasConceptScore W4232912661C61511704 @default.
• W4232912661 hasConceptScore W4232912661C71924100 @default.
• W4232912661 hasConceptScore W4232912661C72563966 @default.
• W4232912661 hasConceptScore W4232912661C99454951 @default.
• W4232912661 hasIssue "4_suppl" @default.
• W4232912661 hasLocation W42329126611 @default.
• W4232912661 hasOpenAccess W4232912661 @default.
• W4232912661 hasPrimaryLocation W42329126611 @default.
• W4232912661 hasRelatedWork W2028827184 @default.
• W4232912661 hasRelatedWork W2101180062 @default.
• W4232912661 hasRelatedWork W2146312028 @default.
• W4232912661 hasRelatedWork W2397726512 @default.
• W4232912661 hasRelatedWork W2562773968 @default.
• W4232912661 hasRelatedWork W3142026086 @default.
• W4232912661 hasRelatedWork W3146277049 @default.
• W4232912661 hasRelatedWork W3209693064 @default.
• W4232912661 hasRelatedWork W4200337742 @default.
• W4232912661 hasRelatedWork W4246588393 @default.
• W4232912661 hasVolume "31" @default.
• W4232912661 isParatext "false" @default.
• W4232912661 isRetracted "false" @default.
• W4232912661 workType "article" @default.